Summary
Pfizer Inc. (PFE) has officially announced the completion of its acquisition of Seagen Inc. through a merger, effective December 14, 2023. This significant transaction involved Pfizer's wholly owned subsidiary, Aris Merger Sub, Inc., merging with and into Seagen, with Seagen now operating as a subsidiary of Pfizer. The acquisition details specify that each outstanding share of Seagen common stock was converted into a cash payment of $229.00 per share, subject to certain exceptions, and Seagen equity awards were also converted or adjusted accordingly.
Key Highlights
- 1Pfizer has successfully completed the acquisition of Seagen Inc. via a merger, effective December 14, 2023.
- 2The transaction sees Seagen become a wholly owned subsidiary of Pfizer.
- 3Seagen shareholders will receive $229.00 in cash for each share of Seagen common stock they held.
- 4Outstanding Seagen equity awards have been converted into cash-based awards or adjusted according to the merger agreement.
- 5This filing serves as an amendment to a previous report, confirming the completion of the merger.
- 6A press release dated December 14, 2023, was issued to announce the completion of the transaction.